FDA supports tighter restrictions on hydrocodone
WASHINGTON — The Food and Drug Administration is recommending tighter restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the United States.
In a major policy shift, the agency said in an online notice on Thursday that hydrocodone-containing drugs should be subject to the same restrictions as other narcotic drugs such as oxycodone and morphine.
More than a decade has passed since the Drug Enforcement Agency asked the FDA to reclassify hydrocodone so that it would be subject to the same restrictions as other opioid drugs. The FDA did not issue a formal announcement about its decision, which has long been sought by many patient advocates, doctors and lawmakers.
In early December, the FDA says it will formally request that hydrocodone be classified as a Schedule II drug, limiting who can write a prescription and how many times it can be refilled.
Show commenting policy
TribLive commenting policy
- Report: DEA prostitutes paid by cartel
- Jackson Jr. leaves prison for halfway house
- Global warming is slowing down the circulation of the oceans — with potentially dire consequences
- Bergdahl, speaking for 1st time, claims 12 attempts to flee Taliban
- Feds arrest guardsman, cousin for terror plot on military facility
- Watchdog: Policy over visas broke, but not law
- Special operations troops are denied commercial intelligence analysis software for missions
- Balanced GOP budget blueprint nears Senate OK
- House OKs overhaul of Medicare, keeps kids insurer
- $140M Picasso likely to set auction record
- Damaged Jersey shore pier to be rebuilt